close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Vifor Pharma

Publication of definitive end result for Vifor Pharma tender offer
From Vifor Pharma
Via Business Wire
Vifor Pharma reports sustained growth in 2021
From Vifor Pharma
Via Business Wire
Vifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa®
From Vifor Pharma
Via Business Wire
First patient enrolled in phase-IIa study of vamifeport in patients with sickle cell disease
From Vifor Pharma
Via Business Wire
Vifor Pharma appoints Hervé Gisserot as new Chief Commercial Officer and member of the Executive Committee
From Vifor Pharma
Via Business Wire
Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury
From Vifor Pharma
Via Business Wire
Tickers ANGN
Vifor Pharma announces changes to the Executive Committee as CFO retires
From Vifor Pharma
Via Business Wire
Vifor Pharma to spearhead development of vascular calcification field, through acquisition of Sanifit Therapeutics and Inositec AG
From Vifor Pharma
Via Business Wire
Vifor Pharma announces changes to its Executive Committee
From Vifor Pharma
Via Business Wire
Vifor Pharma reports strong H1 2021 growth, on track to meet full year guidance1
From Vifor Pharma
Via Business Wire
Abbas Hussain Appointed as New Chief Executive Officer of Vifor Pharma
From Vifor Pharma
Via Business Wire
Vifor Pharma to revise DIAMOND study, readout expected in H2 2021
From Vifor Pharma
Via Business Wire
Vifor Pharma and Angion announce completion of enrollment in phase-II study of ANG-3777 for cardiac-surgery associated acute kidney injury
From Vifor Pharma
Via Business Wire
First patient enrolled in CARE-HK in HF to evaluate role of Veltassa® (patiromer) in enabling RAASi treatment
From Vifor Pharma
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today